Femtogenix, Ltd. was founded in 2015 as a spin-out company from King’s College London (KCL) with RCT providing the initial Series A investment. The focus of the company is to discover and develop next generation DNA-interactive payload molecules for use in antibody-drug conjugates. The payload molecules are designed through a development platform combining proprietary computational chemistry techniques, and founder know-how gained from more than 50 years of experience in DNA-targeted drug discovery and development.
Femtogenix’s drug discovery platform allows the company to design molecules capable of binding reversibly and/or irreversibly to DNA, in a sequence-interactive manner, leading to exquisite cytotoxicity toward tumor cells. When attached to antibodies or other targeting moieties, these potent cytotoxic agents can be delivered directly to tumors with minimal general systemic toxicities for patients. The company’s management and scientific teams consist of highly experienced scientists with the expertise to translate the novel platform into tangible results for cancer patients.